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1 These authors contributed equally to this work.Increased modiﬁcation of proteins with O-linked N-acetylglucosamine (O-GlcNAc) has been impli-
cated in the development of diabetic cardiomyopathy. We used the well-characterized ES cells
(Nkx2.5GFP knock-in ES cells), to investigate the role of O-GlcNAcylation in cardiomyocyte develop-
ment. O-GlcNAcylation decreased in differentiating ES cells, as did the expression of O-GlcNAc trans-
ferase. Increasing O-GlcNAcylation with glucosamine or by inhibiting N-acetylglucosaminidase
(streptozotocin or PUGNAc) decreased the number of cardiomyocyte precursors and cardiac-speciﬁc
gene expression. On the other hand, decreasing O-GlcNAcylation with an inhibitor of glutamine
fructose-6-phosphate amidotransferase (6-diazo-5-oxo-norleucine) increased cardiomyocyte pre-
cursors. These results suggest that excessive O-GlcNAcylation impairs cardiac cell differentiation
in ES cells.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Diabetes markedly increases the risk of cardiovascular disease
and heart failure [1]. The risk of congenital heart defects is also
increased in infants of diabetic mothers [2]. In diabetics, the
hyperglycemic condition is attributable to the development of
diabetic cardiomyopathy, a process believed to be mediated by
several factors including increased modiﬁcation of proteins with
O-linked N-acetylglucosamine (O-GlcNAc) [1,3–5]. O-GlcNAcyla-
tion of nucleocytoplasmic proteins at serine and threonine resi-
dues is an important mechanism regulating signal transduction
and cellular responses to nutrition and various stresses [6,7].
Addition of O-linked N-acetylglucosamine is catalyzed by O-Glc-
NAc transferase (OGT) and removal of O-GlcNAc is catalyzed by
N-acetylglucosaminidase (O-GlcNAcase). O-GlcNAcylation is achemical Societies. Published by E
arch Center, Seoul National
epublic of Korea. Fax: +82 2
im), chojw311@yonsei.ac.krhighly dynamic and reversible process under certain pathophys-
iological circumstances [7]. Under hyperglycemic conditions
commonly observed in diabetes, glucose uptake stimulates the
hexosamine biosynthetic pathway (HBP), which produces UDP-
GlcNAc (uridine diphosphatide GlcNAc), a substrate for O-GlcNAc
modiﬁcation [6]. Excess O-GlcNAcylation has been detected in
the pancreas, corneas, coronary endothelial cells, and atheroscle-
rotic plaques of diabetic patients and laboratory animals [8–10].
Numerous skeletal muscle proteins have recently been shown to
be O-GlcNAcylated, and variations in O-GlcNAc levels are associ-
ated with the development of skeletal muscle atrophy [11,12].
Increased O-GlcNAcylation, in particular, is implicated in im-
paired cardiac myocyte function and the development of diabetic
cardiomyopathy, a condition associated with cardiomyocyte loss
[3,5,7,13]. However, relatively little is known about the effect of
O-GlcNAcylation on the development of cardiomyocytes from
embryonic stem (ES) cells.
ES cells can differentiate into derivatives of all three primary
germ layers, including cardiomyocytes and are considered one of
the most promising sources of cells for transplantation therapy
as well as a useful model system for studying mechanisms of
cell differentiation in vitro [14]. We previously established the ES
cell line, Nkx2.5GFP, to track cardiac cell lineages during mouselsevier B.V. All rights reserved.
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(GFP) gene is knocked in to the Nkx2.5 locus [15]. Nkx2.5 is a
homeobox-containing cardiac transcription factor that is expressed
in the heart primordium throughout the course of development as
well as in cardiomyocytes. This cardiac protein plays a pivotal role
in heart development [16]. Here, we used Nkx2.5GFP ES cells to
determine whether alterations in O-GlcNAcylation affect the devel-
opment of cardiomyocytes. We provide evidence that excessive O-
GlcNAcylation impairs cardiac cell differentiation in ES cells, an ef-
fect that may contribute to diabetic cardiomyopathy.2. Materials and methods
2.1. ES cell culture and differentiation
Nkx2.5GFP cells were maintained and differentiated as previ-
ously described [15]. Brieﬂy, ES cells were routinely grown on gel-
atinized dishes without feeder cells. ES cells were grown in
Glasgow-modiﬁed Eagles medium (Sigma–Aldrich, St. Louis, MO)
supplemented with 1000 U/ml leukemia inhibitory factor (ESGRO,
Chemicon International Inc., Temecula, CA) and 100 lg/ml hygro-
mycin (Invitrogen Corp., Carlsbad, CA). Differentiation of ES cells
was induced through the formation of embryoid bodies (EBs).
EBs were differentiated for 4–11 days. EBs were treated at day 5
with one of the following inhibitors: streptozotocin (STZ, 1–
3 mM), PUGNAc (50–100 lM), glucosamine (GlcN, 1–5 mM), or
the glutamine fructose-6-phosphate amidotransferase (GFAT)
inhibitor, 6-diazo- 5-oxo-norleucine (DON, 5–10 lM).
2.2. Real-time RT-PCR
Total RNA was isolated from ES cells and EBs using TRIzol Re-
agent (Invitrogen) and then treated with DNaseI (Promega Corp.,
Madison, WI) to eliminate genomic DNA. Complementary DNA
was synthesized using SuperScript II reverse transcriptase (Invitro-
gen). Real-time PCR was performed using QuantiTect SYBR Green
PCR kits (QIAGEN, Valencia, CA), and ampliﬁed products were ana-
lyzed using the ABI PRISM 7700 Sequence Detection System (Ap-
plied Biosystems, Foster City, CA). The gene-speciﬁc primers used
are indicated in Table 1.
2.3. Flow cytometry
Cardiomyocytes were monitored by analysis of GFP levels using
ﬂow cytometry. To detect Nkx2.5GFP cells, we dissociated EBs into
single cells using 0.25% trypsin-EDTA and resuspended the single
cells in Hank’s balanced salt solution containing 1% bovine serum
albumin and 2.5 lg/ml propidium iodide. This suspension was
then analyzed on a Calibur ﬂow cytometer (BD Biosciences, San
Jose, CA) using standard procedures.Table 1
Primer list for real-time PCR to detect differentiation of ES cells.
Gene Sense sequence
Antisense sequence
Nkx2.5 50-CAAGTGCTCTCCTGCTTTCC-30
50-GGCTTTGTCCAGCTCCACT-30
b-MHC 50-CTACAGGCCTGGGCTTACCT-30
50-TCTCCTTCTCAGACTTCCGC-30
Cadherin-5 (Cdh-5) 50-AGACACCCCCAACATGCTAC-30
50-GCAAACTCTCCTTGGAGCAC-30
Fetal liver kinase-1 (Flk-1) 50-GGCGGTGGTGACAGTATCTT-30
50-CTCGGTGATGTACACGATGC-30
GATA-1 50-AGCATCAGCACTGGCCTACT-30
50-AGGCCCAGCTAGCATAAGGT-302.4. Western blot analysis
Cells were harvested and resuspended in 20 mM Tris–HCl buffer
(pH 7.4) containing a protease inhibitor mixture (0.1 mM phenyl-
methylsulfonyl ﬂuoride, 5 lg/ml aprotinin, 5 lg/ml pepstatin A,
and 1 lg/ml chymostatin). Proteins were separated by SDS–PAGE
and transferred to nitrocellulose membranes. The membrane was
blocked with 5% non-fat dry milk in Tris–buffered saline and then
incubated with primary antibodies. Blots were developed using
peroxidase-conjugated secondary antibodies and visualized with
enhanced chemiluminescence reagent (Amersham Biosciences,
UK) according to the manufacturer’s recommendations.
2.5. Statistical analysis
Data are presented as means ± S.E and represent at least three
independent experiments. Group means were compared using
the Student’s t-test. Values of P 6 0.05 were accepted as
signiﬁcant.3. Results
3.1. Reduction in protein O-GlcNAcylation during spontaneous cardiac
development of ES cells
We investigated the levels of O-GlcNAcylation in nucleocyto-
plasmic proteins in ES cells and EBs. Previous studies reveal that
cardiac precursor cells (Nkx2.5GFP cells) can be detected in EBs
using ﬂow cytometry after 5 days of differentiation and that car-
diac myosin heavy chain (MHC) is expressed in 7-day-old EBs
[15,17]. O-GlcNAcylation levels gradually decreased in developing
EBs when compared with ES cells. Spontaneously beating EBs ﬁrst
appeared at day 7 along with a 40% (±13.5) decrease in O-GlcNAcy-
lation (Fig. 1A and B). By day 10, O-GlcNAcylation levels began to
recover and were approximately 54% of levels seen in EBs (Fig. 1B).
3.2. Changes in OGT protein expression during spontaneous cardiac
development of ES cells
We determined whether cardiac differentiation-associated
changes in O-GlcNAcylation were accompanied by changes in the
expression of OGT, the enzyme that catalyzes O-GlcNAcylation.
OGT levels were decreased by approximately 40% at 7 days
(Fig. 1C and D), the time at which EBs exhibit spontaneous beating
[15]. In addition, expression of cardiac MHC protein was ﬁrst de-
tected at this time (Fig. 1C).
3.3. Effects of GlcN and DON on spontaneous cardiogenesis of ES cells
GlcN is known to increase O-GlcNAcylation of many proteins by
increasing metabolite ﬂux through this pathway. Conversely, DON
decreases O-GlcNAcylation by inhibiting the GFAT enzyme, which
is the rate-limiting enzyme of the HBP. GlcN-induced O-GlcNAcyla-
tion greatly decreased the number of Nkx2.5GFP cells (Fig. 2). In
contrast, suppression of O-GlcNAcylation with DON slightly in-
creased the number of these cardiac precursors (Fig. 2). To evaluate
whether this inhibitory effect is speciﬁc for cardiac cells/progeni-
tors or this is a generic inhibition of mesoderm differentiation/
speciﬁcation, real-time RT-PCR for fetal liver kinase-1 (Flk-1)
[18,19], cadherin-5 (Cdh-5) [20], and GATA-1 [21], which marks
the commitment of mesodermic cells toward endo-hematopoietic
lineages. GlcN or DON decreased the levels of Cdh-5 and Flk-1 tran-
scripts (Supplementary data). The treatment with DON decreased
the level of GATA-1 transcript, but GlcN has no signiﬁcant change
in GATA-1 transcript (Supplementary data).
Fig. 1. Alterations in protein O-GlcNAcylation and O-GlcNAc transferase (OGT) expression in developing embryoid bodies (EBs). (A) Western blot analysis of
nucleocytoplasmic protein O-GlycNAcylation in EBs differentiated for 0, 5, 7, or 10 days. (B) Quantiﬁed O-GlcNAcylation levels expressed as a percent of levels in ES cells.
(C) Western blot analysis of OGT in EBs differentiated for 0, 5, 7, or 10 days. (D) OGT levels are expressed as a percent of OGT levels in ES cells. All values are presented as the
means ± S.E. of three independent experiments. *P 6 0.05 vs. day 0.
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STZ is a glucosamine analogue and an inhibitor of O-GlcNAcase.
EBs were treated with STZ at day 5 to investigate the role of O-Glc-
NAcylation in cardiomyocyte development. O-GlcNAcylation was
dramatically increased in 10-day-old EBs treated with STZ (1 or
3 mM) (Fig. 3A). Next, we determined the number of cardiac pre-
cursor cells (Nkx2.5GFP cells) in these STZ-treated (3 mM) 10-
day-old EBs. The number of Nkx2.5GFP cells was signiﬁcantly low-Fig. 2. Effects of 6-diazo-5-oxo-norleucine (DON) and glucosamine (GlcN) on
cardiogenesis. Flow cytometric analysis of Nkx2.5GFP cells in EBs treated with DON
(5 or 10 lM) or GlcN (1 or 5 mM). The number of Nkx2.5GFP cells is expressed as a
percent of Nkx2.5GFP cell number in control EBs. All values are presented as the
mean ± standard error of three independent experiments. *P 6 0.05 vs. control.er in STZ-treated EBs (40%) than in control EBs (Fig. 3B and C).
Cardiomyocyte development was further analyzed by examining
b-MHC and Nkx2.5 expression in 10-day-old EBs treated with
STZ. The level of Nkx2.5 and b-MHC transcripts was remarkably
decreased by STZ treatment (Fig. 3D). In addition, MHC protein lev-
els were decreased by STZ in a dose-dependent manner (Fig. 3E).
Accordingly, spontaneous beating was observed in all untreated
EBs, but STZ treatment suppressed spontaneous cardiac beating
in 90% of the EBs (Fig. 3F). The level of the Flk-1, Cdh-5 and
GATA-1 transcripts in STZ-treated EBs was evaluated by real-time
RT-PCR. STZ treatment remarkably decreased the level of Flk-1 and
Cdh-5 transcripts but increased the level of GATA-1 transcript was
signiﬁcantly (Supplementary data). Our result showed excessive O-
GlcNAcylation by treatment with STZ and GlcN suppressed the
development of mesodermic cells toward cardiac and endothelial
lineages (Nkx2.5, Flk-1, or Cdh-5 positive cells) but not hematopoi-
etic lineages (GATA-1 positive cells).
3.5. Effects of PUGNAc on spontaneous cardiogenesis of ES cells
PUGNAc is a potent in vitro and in vivo O-GlcNAcase inhibitor
[22]. Treatment of 5-day-old EBs with PUGNAc (50 or 100 lM)
remarkably increased O-GlcNAc levels in 10-day old EBs (Fig. 4A).
The number of Nkx2.5GFP cells was decreased by approximately
40% in PUGNAc (80 lM)-exposed EBs compared to control EBs
(Fig. 4B). PUGNAc (100 lM) decreased levels of both the cardiac-
speciﬁc proteins, MHC and cardiac troponin T (cTnT) (Fig. 4C).
4. Discussion
In this study, we provide evidence that a reduction in protein O-
GlcNAcylation is critical for the development of cardiomyocytes
Fig. 3. Effect of streptozotocin (STZ) on cardiogenesis. (A) Western blot analysis of protein O-GlcNAcylation in embryoid bodies (EBs) treated with or without STZ (1 or 3 mM).
(B) Representative ﬂow cytometric analysis of the Nkx2.5GFP population in EBs treated with or without STZ (3 mM). (C) The number of Nkx2.5GFP cells expressed as a percent
of Nkx2.5GFP number in control EBs. (D) Real-time RT-PCR analysis of Nkx2.5 and b-MHC in EBs treated with or without STZ (3 mM). b-Myosin heavy chain (b-MHC) and
Nkx2.5 mRNA levels were normalized to GAPDH mRNA levels, which served as an internal control. (E) Western blot analysis of myosin heavy chain in EBs cultured in the
presence or absence STZ (3 mM). (F) The number of beating EBs treated with or without STZ was counted under a microscope. The number of beating EB is expressed as a
percent of beating EB number in control EBs. All values are presented as the means ± S.E.r of three independent experiments. *P 6 0.05 vs. control.
Fig. 4. Effect of PUGNAc on cardiogenesis. (A) Western blot analysis of O-GlcNAcylated proteins from embryoid bodies (EBs) cultured with or without PUGNAc (50 or
100 lM). (B) Flow cytometric analysis of Nkx2.5GFP cells. The number of Nkx2.5GFP cells is expressed as a percent of Nkx2.5GFP cell number in control EBs. (C) Western blot
analysis of myosin heavy chain (MHC) and cardiac troponin T (cTnT) in EBs cultured in the presence or absence PUGNAc (100 lM). All values are presented as the means ± S.E.
of three independent experiments. *P 6 0.05 vs. control.
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genesis, an effect that may contribute to diabetic cardiomyopathy.
Increased HBP ﬂux, concomitant to an increase in protein O-GlcNA-
cylation, has been implicated in the development of diabetic car-
diomyopathy [3,5,7,23,24].
The adverse cardiac effects of diabetes are not limited to adults.
The risk of congenital anomalies is increased in infants of diabetic
mothers and is estimated to be between 2.5% and 12% [2]. Neo-
nates born to mothers with diabetes mellitus have a signiﬁcantly
increased risk of congenital heart diseases such as patent ductus
arteriosus, patent foramen ovale, atrial septal defect, small muscu-lar ventricular septal defect, mitral valve prolapse, and pulmonary
stenosis [25]. Whether alterations in O-GlcNAcylation may account
for these congenital heart defects remains uncertain.
Here, we found that O-GlcNAcylated proteins gradually de-
creased at initiation of cardiac development. This suggests that
the stage of cardiac cell development correlates with the level of
O-GlcNAcylation. The ﬁnding that reduced O-GlcNAcylation in
developing EBs was accompanied by a decrease in OGT suggests
that down regulation of OGT levels contributes to this effect. Our
ﬁndings reveal that a decrease in protein O-GlcNAcylation not only
accompanied cardiomyocyte development but also played an
2478 H.-S. Kim et al. / FEBS Letters 583 (2009) 2474–2478essential role in this process. The ability of known O-GlcNAcase
inhibitors (STZ and PUGNAc) to decrease cardiac precursor cells
(Nkx2.5GFP cells), the levels of cardiac-speciﬁc proteins (MHC
and cTnT), and beating EBs shows that increased protein O-GlcNA-
cylation impairs the development of cardiomyocytes from ES cells.
These results are consistent with the ﬁnding that increased HBP
ﬂux by treatment with GlcN decreased Nkx2.5GFP cells and de-
creased HBP ﬂux by treatment with DON slightly increased the
number of these cells. Cumulatively, these data suggest that O-Glc-
NAcylation either directly or indirectly regulates cardiomyocyte
development during spontaneous cardiogenesis of ES cells. More-
over, they support the notion that dysregulation of pathways lead-
ing to O-GlcNAc formation plays an important role in the
development of congenital heart disease. However, a number of
important questions remain regarding the relationship between
O-GlcNAc and critical proteins (Nkx2.5, Tbx5, or GATA4) regulating
cardiac development during diabetes.
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